Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
- Therapeutic Areas
Our expertise in the industry
Merck, Gilead to co-develop combined HIV treatmentsMerck and Gilead have announced a collaboration to investigate Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s inve...
AstraZeneca/ Oxford resumes the trial of their COVID-19 vaccine in the UKAfter receiving a go-ahead from the UK’s Medicines Health Regulatory Authority, AstraZeneca and the University of Oxfor...
Researchers call out Gilead over the diversity of remdesivir trialsResearchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluat...
Sanofi licenses NK cells of Kiadis to boost the efficacy Sanofi has licensed the natural killer (NK) cells from Kiadis Pharma for use in combination with its multiple myeloma drug Sarclis...
Intercept Pharmaceuticals receives a clear rejection from the FDA for its NASH drug, Obeticholic acid (OCA)Intercept Pharmaceuticals announced the issuance of a Complete Response Letter (C...
Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients. The company plans to explore the anti-inflammatory responses that were w...
FDA permits COVID-19 treatments with blood from survivorsThe FDA revealed the convalescent plasma use that is derived from the donated blood of people that have recovered from COVID-19 and tha...
Gilead Sciences has announced to purchase an Immuno-oncology company Forty Seven for USD 95.50 per share, totalling up to a deal value of USD 4.9 billion.By acquiring Forty Seven – named afte...
Beta thalassemia, globally affects almost 288,000 people, with an incidence of 60,000 cases every year. A rare monogenic genetic disease, beta-thalassemia is caused by more than 200 mutations of t...
NICE Rejects Gilead Sciences’ Yescarta on Cost ConcernsThe United Kingdom’s government-funded health service isn’t being so nice to Gilead Sciences’ CAR-T blood cancer treatment Yescar...
Human Immunodeficiency Virus or HIV is a species of Lentivirus (genus of retrovirus) th...
Progress is driven by innovation. When it comes to developing novel medications and the...
The HIV-1 treatment market for naïve and experienced patients is evolving consistently....
The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...
Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
